Pyridoxamine improves survival and limits cardiac dysfunction after MI.

Area of Science:

• Cardiovascular Research
• Pharmacology
• Biochemistry

Background:

• Advanced glycation end products (AGEs) are implicated in heart failure progression.
• The efficacy of AGEs-limiting treatments in preventing post-myocardial infarction (MI) cardiac remodeling is not well understood.

Purpose of the Study:

• To investigate the potential of pyridoxamine (PM) to mitigate adverse cardiac outcomes following MI.
• To assess PM's effect on AGEs formation, cardiac collagen content, and left ventricular remodeling in a rat MI model.

Main Methods:

• Rats underwent MI surgery or sham procedure; MI rats received PM treatment or no treatment.
• Cardiac function was evaluated using echocardiography and hemodynamic measurements 8 weeks post-surgery.
• Interstitial collagen levels (Total, Type I, Type III) were quantified via Sirius Red staining and microscopy.

Main Results:

• PM pre-treatment significantly improved survival rates in MI rats and reduced plasma AGEs levels.
• PM-treated MI rats exhibited improved diastolic function, indicated by reduced left ventricular end-diastolic pressure and tau.
• Reduced collagen content, particularly cross-linked collagen type I in the peri-infarct zone, correlated with preserved diastolic function.

Conclusions:

• Pyridoxamine treatment effectively lowers AGEs levels and reduces cardiac collagen accumulation in a rat MI model.
• PM administration mitigates maladaptive cardiac remodeling and improves cardiac function post-MI.
• Targeting AGEs formation represents a promising therapeutic strategy for preventing and treating adverse remodeling after myocardial infarction.